The incoming EU Health Technology Assessment (HTA) Regulation will “positively impact” the assessment of new technologies for rare diseases, according to Virginie Bros-Facer, CEO of EURORDIS-Rare Diseases Europe.
“The regulation really should enhance the transparency of assessments” according to Bros-Facer, who became EURORDIS’s CEO in March. “That can only be a good thing for those new, innovative treatments,”...
Key Takeaways
- The new EU HTA Regulation could help the developers of rare diseases to generate the data required for health technology assessments, Virginie Bros-Facer, the CEO...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?